Mark O. Whitaker

机构：GlaxoSmithKline (United Kingdom) · ORCID：0000-0003-3062-2129

发表论文 8 篇 · 总被引 309 次 · h-index 5

代表论文

• Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: Pharmacological basis for a therapeutic approach (1980 · Prostaglandins · 被引 130)
• Triene prostaglandins: Prostaglandin D 3 and icosapentaenoic acid as potential antithrombotic substances (1979 · Proceedings of the National Academy of Sciences · 被引 124)
• A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties (2009 · Bioorganic & Medicinal Chemistry Letters · 被引 25)
• Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology (2022 · Pharmaceutical Research · 被引 12)
• Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 (2021 · Pharmaceutical Research · 被引 12)
• PGD3 is the mediator of the antiaggregatory effects of the trienoic endoperoxide PGH3. (1980 · PubMed · 被引 5)